Recruiting
Phase 2

Umbilical Mesenchymal Stromal Cells

Sponsor:

Ottawa Hospital Research Institute

Code:

NCT05969275

Conditions

Septic Shock

Sepsis

Pathologic Processes

Shock

Systemic Inflammatory Response Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Allogeneic umbilical cord-derived human mesenchymal stromal cells

Placebo

Study Details

Brief summary:

Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients with septic shock. The Cellular Immunotherapy for Septic Shock Phase I (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (UC-CISS II) at several Canadian academic centres which will evaluate intermediate measures of clinical efficacy (primary outcome), as well as biomarkers, safety, clinical outcome measures, and a health economic analysis (secondary outcomes).

Conditions

Septic Shock

Sepsis

Pathologic Processes

Shock

Systemic Inflammatory Response Syndrome

Study ID

NCT05969275

Start date

Feb 14, 2024

Status verified date

Dec, 2024

Completion date

Mar 31, 2027

Anticipated

Primary completion date

Sep 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

A participant must meet all the following inclusion criteria at time of randomization to be eligible:

1. At least 18 years of age AND
2. Requirement for admission to the intensive care unit AND
3. Index admission to the intensive care unit AND
4. Cardiovascular organ failure for at least 1 consecutive hour defined by the requirement of at least 5 mcg/min of norepinephrine or 100 mcg/min of phenylephrine or 0.03 U/min vasopressin AND
5. Clinician impression that cardiovascular organ failure is related to infection AND
6. There is at least 1 other acute organ failure according to modified individual Sequential Organ Failure Assessment Scores within 24 hours of meeting Cardiovascular organ failure defined by:

1. Respiratory failure: invasive or non-invasive mechanical ventilation with a positive end expiratory pressure (PEEP) >/= 5 cm H2O and a partial pressure of oxygen/fractional inspired oxygen concentration (P/F ratio </= 200), OR high-flow nasal canula oxygen therapy (minimum total flow rate of 30 lpm and 40% FiO2); OR
2. Hematological failure: platelet count of </= 100 X 10\^9/L OR
3. Acute kidney injury: acute renal insufficiency with a creatinine of >/= 200 umol/L, or the requirement for new renal replacement therapy, or for participants with known chronic renal failure but not on dialysis, a 50% increase in their baseline creatinine concentration OR
4. Organ hypoperfusion: a lactate >/= 4 mmol/L

Acute organ failures that meet eligibility criteria must not have been present for greater than 48 hours prior to meeting the eligibility criteria.

Exclusion Criteria:

Patients will be excluded if they have at least one of the following at time of randomization:

1. Another form of shock (cardiogenic, hypovolemic, obstructive) OR
2. History of known chronic pulmonary hypertension with a WHO functional class of IV OR
3. History of severe chronic pulmonary disease requiring home oxygen OR
4. History of severe chronic cardiac disease including congestive heart failure or valvular dysfunction with a New York Heart Association Functional class IV or severe chronic ischemic heart disease with a Canadian Cardiovascular Society angina class score IV OR
5. History of severe chronic liver disease (Child-Pugh Class C or model for end stage liver disease (MELD) Score >= 15) OR
6. Malignancy in previous 1 year (excluding resolved non-melanoma skin cancer) OR
7. Treating physician impression that death is imminent within the 12 hours after meeting eligibility criteria OR
8. Pregnant or lactating OR
9. Family or patient not committed to aggressive care

Study Design

Enrollment

296 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs)

Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells

placebo comparator: Placebo

Intravenous infusion of placebo, with excipients

Interventions

Allogeneic umbilical cord-derived human mesenchymal stromal cells

Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells

Placebo

Intravenous infusion of placebo, with excipients

Primary outcome measure

  • Days free from mechanical ventilation and/or vasopressors and/or renal replacement therapy [ Time Frame: Through to 28 days post-randomization ]

Central Contacts and Locations

Central contacts

Locations

The Ottawa Hospital (General Campus)

Recruiting

Ottawa, Ontario, Canada, K1H 8L6

Contacts

Irene Watpool, RN

UCCISS@ohri.ca

Principal Investigator:

Lauralyn McIntyre, MD

The Ottawa Hospital (Civic Campus)

Recruiting

Ottawa, Ontario, Canada, K1Y 4E9

Contacts

Rebecca Porteous, RN

UCCISS@ohri.ca

Principal Investigator:

Lauralyn McIntyre, MD

More Information

Sponsor

Ottawa Hospital Research Institute

Last update posted

Dec 5, 2024

Last verified

Dec, 2024

Keywords

  • Mesenchymal Stem Cells
  • Mesenchymal Stromal Cells
  • Randomized Controlled Trial
  • Cryopreserved
  • Allogeneic
  • Umbilical Cord
  • Phase II
  • Sepsis
  • Septic Shock

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ottawa Hospital Research Institute on 2024-12-05.